Lundbeck Reveals Promising Phase 1b Results for Parkinson's Treatment at AD/PD™ 2026

Lundbeck's New Phase 1b Data on Lu AF28996 at AD/PD™ 2026

Lundbeck, a renowned biopharmaceutical company based in Denmark, has made a significant announcement regarding its investigational treatment Lu AF28996 for advanced Parkinson's disease. During the 2026 Alzheimer’s and Parkinson’s Disease Conference (AD/PD™) held in Copenhagen, the company unveiled new data from a Phase 1b proof-of-mechanism trial that highlights the drug's safety, tolerability, and early clinical efficacy signals.

The Phase 1b trial evaluated Lu AF28996, a novel compound active on dopamine D1/D2 receptors, administered orally to individuals suffering from advanced Parkinson's disease. The outcomes from the trial indicate that the drug was generally well tolerated among participants and demonstrated early signals suggesting its potential effectiveness in managing the symptoms of Parkinson's disease. These promising outcomes bolster Lundbeck’s commitment to further clinical development of the drug.

Parkinson's disease, particularly in its advanced stages, is often characterized by significant motor fluctuations that lead to episodes of reduced mobility, scientifically referred to as “OFF” times. These mobility challenges can disrupt the daily lives of patients, and existing treatments may result in unwanted motor complications such as dyskinesia. Lundbeck aims to tackle these challenges by introducing innovative therapies that prioritize patient comfort and ease of use.

Johan Luthman, EVP and Head of Research and Development at Lundbeck commented, “Phase 1b patient trials are crucial for understanding the safety profile and biological activity of new investigational therapies. The data we present here provide supportive evidence for evaluating the potential of Lu AF28996 in treating advanced Parkinson's disease.”

In conjunction with Lou AF28996, Lundbeck also presented research related to Multiple System Atrophy (MSA), another serious neurodegenerative condition that currently lacks approved therapies. The presentations emphasized Lundbeck’s advancements in understanding MSA's progression and the utilization of Bayesian progression modeling which can assist in assessing clinical trial outcomes. Acknowledging patient perspectives during trial design and advances in biomarker development for earlier diagnosis were also prominent topics discussed.

Throughout the AD/PD™ 2026 conference, Lundbeck showcased the strength of its research and development pipeline in movement disorders with multiple discussed projects focused on Parkinson’s disease and MSA. This commitment highlights the company’s dedication to developing vital therapies for those suffering from severe neurological conditions.

Both Lu AF28996 and the monoclonal antibody amlenetug, which targets extracellular α-synuclein, are currently under investigation and have yet to receive approval from regulatory authorities for clinical use. Both drugs represent Lundbeck’s continued efforts towards advancing treatments in the critical area of brain health.

The research presented at AD/PD™ serves as a testament to Lundbeck’s mission to innovate within the field of neuropharmaceuticals, providing hope for patients with severe neurological disorders. As they move forward with clinical trials, the data from Phase 1b offers a promising pathway toward new options for managing Parkinson's disease effectively.

With over 5,000 employees and a presence in more than 20 countries, Lundbeck's commitment to improving brain health is underscored by their focus on the complexities of neurological and psychiatric conditions, ensuring a future where patients can access effective treatments and experience enhanced quality of life.